The index declined 0.6%, dragged down by life insurers, miners and homebuilders
London’s FTSE 100 index underperformed its European peers on Wednesday, weighed down by heavyweight financials and mining stocks, while Clinigen Group eyed its worst day on record after a downbeat earnings update.
The blue-chip index declined 0.6%, dragged down by life insurers, base metal miners and homebuilders.
Banks lost 1.3%, with Barclays leading the decline. HSBC Holdings dropped 1.2% after Moody’s downgraded its senior insecured debt rating to A3 from A2.
The domestically focused mid-cap FTSE 250 index shed 0.4%.
World stock prices held near record highs as investors bet the Federal Reserve is some way off from tapering its economic stimulus.
It has been a very quiet week. Everyone is waiting for the ECB decision and the U.S. inflation numbers tomorrow. Volumes are very light and there’s not much sort of decisive leadership across sectors, said Ian Williams, economics & strategy research analyst at Peel Hunt.
Compared to the Fed and even the Bank of England, the ECB probably would be a little bit more cautious and the withdrawal of stimulus in the eurozone is further away than it is here or in the U.S., he said.
After breaking above the 7,000 mark in mid-April, the FTSE 100 index has oscillated in a narrow range on concerns that rapid economic growth could lead to higher inflation and faster tightening of ultra-loose monetary policies.
Among stocks, Smith+Nephew climbed 4% to the top of the FTSE 100 index, after Credit Suisse upgraded the medical products maker’s stock to “outperform” from “neutral”.
Clinigen Group tumbled 23% as RBC cut its price target on the stock after the pharmaceutical company forecast annual adjusted EBITDA within the range of 114 million pounds and 117 million pounds, lower than market expectations.
The articles are for information purposes only and Precise Investors shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date.
Precise Investors does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this website, or losses or damage you may incur doing so.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.
Please remember that investments of any type may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.